Antibody expression titers are critical for optimizing screening efficiency in drug discovery and development. While increasing batch sizes and refining downstream processes can address low expression levels, the underlying issue often resides in the DNA sequences utilized. Controlled benchmarking studies are essential for systematically assessing DNA construct design decisions that influence expression outcomes.
In an upcoming webinar, Justin Byers and Daniel Lin-Arlow, PhD, will delve into the role of enzymatic DNA synthesis and innovative DNA construct design in overcoming antibody expression challenges. Byers will present findings from a benchmarking study on various codon-optimization strategies, highlighting how AI-driven codon optimization yielded superior transient expression titers compared to traditional methods. This suggests that complex sequence features, often overlooked, are vital for maximizing gene expression.
Lin-Arlow will showcase Ansa’s enzymatic DNA synthesis technology, emphasizing its advantages for clients engaged in antibody production and synthetic biology. The session will provide insights into how rigorous sequence evaluation can streamline timelines and mitigate expression failures, underscoring the importance of integrating advanced design strategies in the early stages of development.
Start your 7-day trial and see what the database can do →
